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Abstract
Background: Pain from injuries is one of the commonest symptoms in children attending emergency departments
(EDs), and this is often inadequately treated in both the pre-hospital and ED settings, in part due to challenges of
continual assessment and availability of easily administered analgesic options. Pain practices are therefore a key research
priority, including within the field of paediatric emergency medicine. Methoxyflurane, delivered via a self-administered
Penthrox® inhaler, belongs to the fluorinated hydrocarbon group of volatile anaesthetics and is unique among the group
in having analgesic properties at low doses. Despite over 30 years of clinical acute analgesia use, and a large volume of
evidence supporting its safety and efficacy, there is a paucity of randomised controlled trial data for Penthrox®.
Methods: This is an international multi-centre randomised, double-blind, placebo-controlled phase III trial assessing the
efficacy and safety of methoxyflurane delivered via the Penthrox® inhaler for the management of moderate to severe
acute traumatic pain in children and young people aged 6–17 years. Following written informed consent, eligible
participants are randomised to self-administer either inhaled methoxyflurane (maximum dose of 2 × 3ml) or normal
saline placebo (maximum dose 2 × 5ml). Patients, treating clinicians and research nurses are blinded to the treatment.
The primary outcome is the change in pain intensity at 15min after the commencement of treatment, as measured by
the Visual Analogue Scale (VAS) or the Wong-Baker FACES® Pain Rating scale, with the latter converted to VAS values.
Secondary outcome measures include the number and proportion of responders who achieve a 30% reduction in VAS
score compared to baseline, rescue medication requested, time and number of inhalations to first pain relief, global
medication performance assessment by the patient, clinician and research nurse, and evaluation of adverse events
experienced during treatment and during the subsequent 14 ± 2 days. The primary analysis will be by intention to
treat. The total sample size is 110 randomised and treated patients per treatment arm.
Discussion: The Methoxyflurane AnalGesia for Paediatric InjuriEs (MAGPIE) trial will provide efficacy and safety data for
methoxyflurane administered via the Penthrox® inhaler, in children and adolescents who present to EDs with moderate
to severe injury-related pain.
Trial registration: EudraCT, 2016–004290-41. Registered on 11 April 2017.
ClinicalTrials.gov, NCT03215056. Registered on 12 July 2017.
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Background
Pain is the most common symptom in patients requiring
emergency healthcare, with acute trauma frequently the
cause [1, 2]. There are many short-term and long-term
consequences of inadequately treated acute pain, and it
is universally accepted that its management should begin
at the earliest opportunity [3, 4]. In 2012, the Royal Col-
lege of Emergency Medicine [5] identified pain manage-
ment as the most popular indicator for quality of care in
an emergency department (ED). Current standards rec-
ommend the simple and timely sequential process of
pain recognition, assessment, measurement, therapeutic
actions/interventions and reassessment [6]. Pain-relief
regimes work optimally when effective analgesics are
supported by formal protocols and guidelines under-
pinned by staff and patient education.
Patients with traumatic pain often receive inad-
equate analgesia in pre-hospital and ED settings [7,
8]. The reasons for this are multifaceted, but in chil-
dren they likely include challenges such as assessment
tool application, perceived competing clinical prior-
ities, ease/route of drug administration, availability of
therapeutic options and a limited evidence base.
Paediatric emergency physicians have prioritised pain
practices as a key research priority [9]. The ideal an-
algesic for acute pain should have rapid onset of ac-
tion, act over an appropriate and predictable period
of time, be well tolerated and be effective across a
wide range of pain types in different populations. The
time to clinical analgesic effect of oral or topical anal-
gesics is too slow to meet the standards of treating
trauma-related moderate or severe paediatric pain
[10]. Intranasal or inhaled delivery of analgesic agents
allows quick and simple drug administration without
the distress of intravenous cannulation and may help
improve the management of acute moderate to severe
pain in children in pre-hospital and ED settings.
Methoxyflurane (2,2-dichloro-1,1-difluoro-1-methox-
yethane) is a volatile fluorinated hydrocarbon [11]. It is a
colourless liquid with a fruity odour. Methoxyflurane
was first introduced as an inhalational anaesthetic in the
1960s. In the 1970s, due to availability of newer anaes-
thetic agents and case reports of dose-related renal tubu-
lar damage at high anaesthetic doses of long duration,
its use was generally discontinued. However, unlike
other fluorinated anaesthetics, methoxyflurane has anal-
gesic properties at much lower doses, which are not as-
sociated with nephrotoxicity [12].
In Australia, methoxyflurane (Penthrox®) is licensed
for short-term relief of acute pain in adults and children
(including minor surgical procedures), and has been
used for pain relief in sub-anaesthetic doses for over 30
years. The number of administrations has now exceeded
6 million, with only a single report of nephrotoxicity at
recommended analgesic doses. There were confounding
factors in this adult case report [13].
Methoxyflurane is available in 3-ml ampoules contain-
ing pure methoxyflurane to be used in a self-
administered hand-held and portable Penthrox® inhaler,
to a potential maximum recommended dose in 24 h of
two 3-ml vials [14]. Methoxyflurane is absorbed rapidly,
resulting in fast onset of analgesia, usually within 6–10
inhalations [14]. As a non-controlled drug, the prepar-
ation time between prescription and patient administra-
tion is quick, and Penthrox® likely requires less patient
monitoring than opioid analgesics. Methoxyflurane ad-
ministered via the Penthrox® inhaler may eliminate the
need for opioid analgesia for dislocations or fractures,
since the pain relief may be sufficient for reduction or
splinting.
A literature review on the use of methoxyflurane in
EDs and prehospital settings recommended that large,
blinded, placebo-controlled studies investigating its
analgesic efficacy should be conducted [15]. This was
largely addressed in trial MEOF-001 (the STOP trial),
conducted at six sites in the UK between 2011 and
2012 [16]. However, the majority of the participants
were adults, with just 90 adolescent patients (aged
12–17 years) and no younger children. One other
paediatric RCT showed that methoxyflurane was ef-
fective for the treatment of pain associated with
upper limb fractures, but this trial included just 41
patients over the age of 5 years [17].
The Methoxyflurane AnalGesia for Paediatric InjuriEs
(MAGPIE) trial—a well-powered, randomised, blinded,
placebo-controlled trial—therefore aims to determine
whether methoxyflurane is effective and safe in the treat-
ment of moderate to severe injury-related pain in chil-
dren and young people aged 6–17 years.
Methods
Aim
This trial aims to establish the efficacy and safety of me-
thoxyflurane, when self-administered via the Penthrox®
inhaler, in children and adolescents presenting to EDs
with moderate to severe injury-related pain.
Trial design
This is an international multi-centre, randomised, double-
blind, placebo-controlled, explanatory phase III trial asses-
sing the efficacy and safety of methoxyflurane delivered
via the Penthrox® inhaler for the management of moderate
to severe pain associated with minor trauma. Recruitment
and randomisation are stratified by age group bandings of
6–8 years, 9–11 years and 12 to < 18 years in a 2:2:1 ratio.
A trial flowchart is shown in Fig. 1.
Key trial events are outlined in Fig. 2.
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The protocol for this trial has been written in accord-
ance with the Standard Protocol Items: Recommenda-
tions for Trials (SPIRIT) checklist (Additional file 1).
Trial setting
Nine EDs within the UK and Ireland are participating,
selected from the membership of Paediatric Emergency
Research in the UK and Ireland (PERUKI) (www.peruki.
org), a collaborative paediatric emergency medicine re-
search network [18]. Participating sites may be tertiary
or district general hospitals with EDs that treat either
children alone or both children and adults. Site selection
was based on several factors, including previous research
experience, site research infrastructure and number of
Fig. 1 MAGPIE trial flowchart. ED emergency department, MAGPIE Methoxyflurane AnalGesia for Paediatric InjuriEs
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Fig. 2 MAGPIE trial schedule of trial events. MAGPIE Methoxyflurane AnalGesia for Paediatric InjuriEs, UMSS University of Michigan Sedation Scale,
VAS Visual Analogue Scale, WBF-PRS Wong-Baker FACES® Pain Rating scale
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likely recruits estimated from a preparatory service
evaluation.
Trial participants
Inclusion criteria
The following inclusion criteria apply:
 Age ≥ 6 years to ≤ 17 years.
 Attending an ED following minor trauma.
 Pain scores (at screening and just prior to
administration of study treatment) measuring
between 60 and 80 mm on the Visual Analogue
Scale (VAS) [19] or, where the patient is unable to
understand the VAS, pain scores between 6 and 8
using the Wong-Baker FACES® Pain Rating scale
(WBF-PRS).
Exclusion criteria
Patients are not enrolled to the trial if they meet any of
the following criteria:
1. Critical, life-threatening or limb-threatening con-
dition requiring immediate management.
2. Open fractures.
3. Any other clinical condition that may, in the opinion
of the Investigator, impact the patient’s ability to
participate in the trial.
4. Patient deemed not cognitively capable of effectively
self-administering the trial treatment.
5. Treatment with any analgesic agent within 5 h prior
to presentation to the ED, with the exception of
Entonox (50% nitrous oxide and 50% oxygen mixture,
which is prohibited within 30 min prior to
presentation to the ED), diclofenac (which is
prohibited within 8 h prior to presentation to the
ED) or oral morphine (which is prohibited within
10 h prior to presentation to the ED).
6. Chronic pain.
7. Receipt of an investigational medicinal product
(IMP) in the preceding 3 months.
8. Known pregnancy or breastfeeding females.
9. Personal or familial hypersensitivity to
methoxyflurane or any fluorinated anaesthetics.
10. Requirement for oxygen therapy.
11. Known or genetic susceptibility to malignant
hyperthermia or a history of severe adverse
reactions (ARs) in either patient or relatives.
12. Clinically evident respiratory depression.
13. Previous use of methoxyflurane (including as an
IMP).
14. History of signs of liver damage including after
previous methoxyflurane use or halogenated
hydrocarbon anaesthesia.
15. Known significant renal impairment.
16. Altered level of consciousness due to any cause
including head injury, drugs or alcohol.
17. Known significant cardiovascular disease (e.g.
pathological arrhythmia).
18. Inability to participate in telephone follow-up on
day 14 (± 2 days).
Primary outcome
The primary outcome is the change in VAS (including
WBF-PRS scores subsequently converted to VAS values)
at 15 min after the commencement of treatment.
Secondary outcomes—efficacy
 Number and proportion of participants in each arm
who achieve a 30% reduction in VAS score at 15
min.
 Number and proportion of participants in each arm
who achieve a 30% reduction in VAS score at 5, 10
and 20 min.
 Change in pain intensity (VAS) at 5, 10, 15, 20 and
30 min, and every 30 min thereafter until the point
of ED discharge.
 Number and proportion of participants in each arm
requesting rescue medication within 20 min of start
of treatment, and any time during treatment.
 Time to requesting rescue medication.
 Time to first-reported analgesic effect.
 Number of inhalations until first-reported analgesic
effect.
 Whether the patient covered the dilutor hole in the
inhaler during inhalation.
 Global medication performance assessment by patient,
clinician and research nurse, using a 5-point Likert
scale.
Secondary outcomes—safety
 AEs experienced during treatment (not associated
with the underlying trauma).
 Significant changes in physiological parameters or
sedation scores during treatment.
 Evaluation of AEs at 14 ± 2 days following ED
discharge using a follow-up questionnaire that in-
cludes high-output nephrotoxicity.
Screening
Screening commences once a child is registered in the
ED with minor trauma, defined as “a non-critical and
non-limb threatening physical wound or injury of the
tissues”; this definition includes soft tissue injuries, frac-
tures or ligament injuries of the extremities, burns,
penetration by foreign bodies, lacerations, dislocation
and contusions. Trial research nurses identify and screen
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potentially eligible patients. The screening process in-
cludes the measurement of the screening pain score,
using either the VAS or WBF-PRS, which must fall
within the acceptable trial range. The unique participant
screening form records reasons for non-randomisation
where appropriate.
Consent
Eligible patients and their parent or legal guardian are
given sufficient time to read a summary Patient Informa-
tion Sheet (PIS), approved by the Research Ethics Com-
mittee (REC), which contains all essential information
regarding the MAGPIE trial. After the participant has
been offered the opportunity to ask further questions
and agrees to participate, informed consent is taken by a
member of the research team who will remain blinded
to subsequent randomisation and treatment allocation.
For patients under the age of 16 years, written informed
consent is sought from the parent or legal guardian, with
verbal assent from the patient. Competent 16 and 17
year olds provide their own written consent. At the time
of discharge from the ED, a detailed PIS is provided,
which has also been approved by the REC.
Enrolment and randomisation
Randomisation sequences, stratified by age group (6–8
years, 9–11 years and 12 to < 18 years in a 2:2:1 ratio),
are prepared by an independent statistician. Patients are
randomised in the ratio of 1:1 to the active (methoxyflu-
rane) or placebo group. The IMP is packaged according
to the randomisation sequence prepared by the inde-
pendent statistician.
Following consent, an unblinded member of the trial
team enrols the patient to the trial using the Interactive
Web Response System (IWRS). At enrolment, the par-
ticipant is allocated the next randomisation number in
the appropriate stratum. Treatment allocation as per the
randomisation scheme is maintained by allocating IMP
or placebo with the next sequential patient number.
Trial treatments
Methoxyflurane (active treatment) or normal saline (pla-
cebo) are administered by inhalation via the hand-held
Penthrox® inhaler, and are self-administered by the pa-
tient under the supervision of a research nurse who is
trained in administration.
Active treatment
A 3-ml sample of methoxyflurane is vaporised in a Pen-
throx® inhaler. On finishing the dose, the patient can re-
quest a second inhaler containing a further 3-ml dose.
The maximum dose administered is 6 ml of methoxyflu-
rane. The composition of methoxyflurane is detailed in
Table 1.
Methoxyflurane is supplied as 3 ml of liquid in glass
bottles in the IMP pack, and is stored below 30 °C.
Placebo
A 5-ml sample of commercially available sterile 0.9% so-
dium chloride (normal saline) for injection is loaded into
the Penthrox® inhaler. The patient can request a second
inhaler containing a further 5-ml dose. The maximum
dose administered does not exceed 10 ml.
Penthrox® inhaler
The hand-held Penthrox® inhaler is a small, lightweight,
disposable, cylindrical polyethylene device, approxi-
mately 15 cm long in a distinctive green colour, shaped
like a large (green) whistle (Fig. 3).
There is a dilutor hole at the mouthpiece end, which,
when covered with the patient’s index finger, allows a
higher concentration of treatment to be inhaled. The de-
vice contains a polypropylene S-shaped wick, which ab-
sorbs the liquid. An internal one-way valve allows air
and vapour to be inhaled; this closes on expiration to
prevent exhalations (containing a mixture of air, me-
thoxyflurane and carbon dioxide) passing back through
the wick. The inhaler is a single-patient use device,
which prevents cross-contamination between patients,
and can be easily disposed of after use.
To minimise environmental release of methoxyflurane,
an activated carbon (AC) chamber is inserted into the
aperture at the top of the inhaler. The AC adsorbs the
exhaled methoxyflurane without causing any resistance
to inhalation or expiration.
Loading of the Penthrox® inhaler and blinding procedures
The unblinded investigator is responsible for loading
and dispensing Penthrox® inhalers in such a way as to
maintain the blinding for the treating clinician and the
blinded research nurse. The key challenges for maintain-
ing the blinding in the MAGPIE trial are the ability to
distinguish between active IMP and placebo by the ap-
pearance of the container, volume of liquid administered
and smell of methoxyflurane. The inhaler loading occurs
in a closed area which is geographically separated both
from the participant’s treatment area and the location of
blinded research staff.
Each patient is allocated a pack containing two Pen-
throx® inhalers, each with an AC chamber attached, two
containers of either methoxyflurane or sterile normal sa-
line and four sealable plastic bags. Placebo packs include
a container of methoxyflurane which is used for blinding
(see next section). At enrolment, the assigned partici-
pant number (linked to the randomisation number) is
entered on all pack labels. Packs are prepared by an in-
dependent pharmaceutical distributor.
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Each Penthrox® inhaler is loaded by pouring the full
contents of either one 3-ml bottle of methoxyflurane
(active treatment) or one 5-ml ampoule of sterile normal
saline (placebo) into the inhaler, in accordance with the
treatment allocation of the patient. Different volumes of
methoxyflurane and normal sodium chloride are used to
minimise the weight difference because of the significant
solution density difference between methoxyflurane and
0.9% sodium chloride.
The inhaler is placed in a plastic bag, which is
sealed and weighed prior to being dispensed to
blinded investigators. Before sealing the plastic bag
containing a placebo inhaler, several drops of me-
thoxyflurane are placed on the wristband of the pla-
cebo inhaler, so that it is not possible for participants
or blinded investigators to distinguish between active
IMP and placebo based on a masking smell upon
opening the plastic bag.
A second identical inhaler is prepared using the same
treatment allocation. This second inhaler is to be avail-
able if requested by the patient if they deem the first in-
haler is no longer effective. The maximum dose
administered does not exceed 6 ml of methoxyflurane
(2 × 3ml) or 10 ml of placebo (2 × 5ml).
Allocation of investigators to blinded or unblinded
processes is the responsibility of the site Principal Inves-
tigators; once allocated, these investigators may not
switch roles for the duration of the trial.
Administration of trial treatments
The research nurse provides training in the use of the
device to the patient using a demonstration inhaler
which contains no IMP and supports them in its use as
necessary for the duration of IMP administration. Base-
line vital signs (heart rate, blood pressure, respiratory
rate and oxygen saturation) are measured along with an
assessment of baseline sedation level using the Univer-
sity of Michigan Sedation Scale (UMSS) [20].
After randomisation, the baseline (time = 0) pain score
is assessed, to ensure relative stability of pain intensity.
If the baseline pain score has fallen outside the range of
60–80mm on the VAS or 6–8 on the WBF-PRS, the pa-
tient is withdrawn from the trial (randomised but not
treated).
If successfully randomised, the research nurse assists the
participant to self-administer 10 successive inhalations of
the IMP. Participants and parents/legal guardians are ad-
vised that rescue analgesia is available immediately on re-
quest at any time. Permitted rescue medications are
intranasal fentanyl, intranasal diamorphine, intranasal
ketamine, intravenous morphine, oral morphine or Ento-
nox (50% nitrous oxide and 50% oxygen mixture),
dependent on the standard practice of the participating
site and at the discretion of the treating clinician. This ap-
proach is in line with current recommended practice [10]
for the management of moderate to severe pain.
Standard-of-care oral analgesic medications (paracetamol
Table 1 Composition of methoxyflurane
Investigational product Function Each 1 ml contains Each 3 ml contains
Methoxyflurane Active ingredient 99.9% w/w 99.9% w/w
Butylated hydroxytoluene Antioxidant 0.01% w/w 0.01% w/w
Fig. 3 The Penthrox® inhaler
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and ibuprofen) may be administered as concomitant med-
ications alongside rescue medication. Participants who re-
port pain relief due to IMP inhalation are advised to
continue to self-administer additional inhalations, as re-
quired, during their ED attendance.
Trial assessments
Participants are evaluated according to the schedule of
events outlined in Fig. 1.
Pain scores
Pain intensity is re-assessed using the VAS or WBF-PRS
at 5, 10, 15, 20 and 30min after the start of inhalation of
the trial treatment, and every 30 min thereafter until ED
discharge. Additional unscheduled pain scores are
assessed at the time of any other key events, such as
during any injury treatment, prior to rescue medication
administration, prior to premature trial withdrawal or
just prior to ED discharge.
Vital signs and sedation scores
Vital signs (heart rate, blood pressure, respiratory rate
and oxygen saturation) and UMSS are re-assessed at 5,
10, 15, 20 and 30min after the start of inhalation of the
trial treatment, and every 30 min thereafter until ED
discharge.
Other key events
The following events are recorded if and when they
occur:
 Treatment of the patient’s injury, and the start and
end times of such treatment.
 Timing and nature of any AEs (other than those
associated with the underlying minor trauma) and
any associated change in trial treatment
administration.
 Concomitant medication administration.
Global medication performance
Following completion of trial treatment administra-
tion, the patient, research nurse and treating clinician
are each asked to rate the global medication perform-
ance on a 5-point Likert scale (poor, fair, good, very
good, excellent).
Events at the point of ED discharge
Upon completion of trial treatment administration, all
inhalers are collected, placed and sealed in the plastic
bags and returned to the unblinded investigator, who
weighs the inhalers inside their sealed plastic bags
and records the weights following trial treatment
administration.
At the point of discharge, a final pain score and vital
signs are recorded. For patients requiring inpatient ad-
mission, the time of such a decision to admit should be
considered the discharge time in terms of trial activity.
The final injury diagnosis is documented. A single dose
of oral analgesia (paracetamol and ibuprofen) is offered
to all patients unless these have previously been admin-
istered or are contra-indicated. In the case of patients
who are being discharged home, rather than admitted,
instructions are provided to the patient/parent on suit-
able analgesia post discharge (as per standard practice of
participating sites). The patient/parent is provided with
a diary card and asked to record all concomitant medi-
cations and any symptoms experienced from the time of
discharge until the follow-up telephone call. The pa-
tient/parent is advised to contact the named trial doctor
or research nurse in the event of any significant adverse
event (SAE), using the contact information provided on
the PIS. In any cases of SAE, the patient is recalled to
the site for further assessment.
Follow-up
At 14 ± 2 days after discharge from the ED, the research
nurse telephones the patient/parent for safety follow-up.
A set questionnaire is used, and the patient/parent is
asked to refer to the information collated on their diary
card. The following points are covered during the tele-
phone call:
 Any concomitant medication(s) (name and dose of
medication) taken since discharge.
 Any AE, other than those related to the original
injury.
 Presence or absence of specific symptoms and signs,
including those relating to potential nephrotoxicity
and hepatotoxicity.
 In any cases of significant AE, the patient is recalled
to the site for further assessment.
At least three attempts are made to contact the patient
to collect this follow-up information. If the three at-
tempts are unsuccessful, the patient’s general practi-
tioner is contacted for information on any recent
medical consultations.
Data collection and management
A paper Screening Form and a Data Collection Pro-
forma (DCP) are used to capture trial data in real time.
Patient identification on the DCP is through their
unique trial number, allocated at the time of enrolment.
The DCP becomes the paper source document; however,
it is used in conjunction with the usual hospital practice
for recording medical information.
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On completion of ED trial processes, participant data
are recorded via the InForm Electronic Data Capture
system using an electronic Case Report Form (eCRF).
These data are transcribed by the research nurse or a
delegated data manager from the DCP onto the eCRF.
To ensure accurate, complete and reliable data are col-
lected, IQVIA™ (formerly QuintilesIMS™ Holdings, Inc.),
the Contract Research Organisation for the MAGPIE
trial, provides training to site staff in the form of investi-
gator meetings, site initiation visits or teleconference
training sessions. The data are validated, and discrep-
ancy reports are generated following data entry to iden-
tify discrepancies, such as out of range values,
inconsistencies or protocol deviations based on data val-
idation checks programmed into the eCRF. A full elec-
tronic audit trail is created for data entry and any
subsequent amendments. Prior to submission, each
completed eCRF must be reviewed for accuracy by the
Principal Investigator at the site, corrected as necessary
and then approved. The Investigator’s e-signature serves
to attest that the information contained on the eCRFs
has been reviewed by the Investigator and is true and ac-
curate. The monitor will review the eCRFs and evaluate
them for completeness and consistency. The eCRF is
compared with the source documents to ensure that
there are no discrepancies between critical data.
The sites, the trial database and trial documentation
are subject to quality assurance audit during the course
of the trial by the sponsor or IQVIA™ on behalf of the
sponsor. In addition, inspections may be conducted by
regulatory bodies at their discretion.
Statistical considerations
Statistical analyses are performed by IQVIA™ using SAS®
version 9.4 or higher (SAS Institute, Cary, NC, USA).
Any change to the data analysis methods will be men-
tioned in the statistical analysis plan. Any additional ana-
lysis, and the justification for making the change, will be
described in the Clinical Trial Report.
Sample size estimation
The sample size calculations assume a treatment differ-
ence to placebo of 12.4 mm in adolescents (based on in-
terim 15-min data from the MEOF-001 trial [16]) and
14mm in younger children, leading to a combined over-
all difference to be detected of 13.3 mm. The expected
variability is higher in younger children (standard devi-
ation (SD) 28mm) than in adolescents (SD 22.5 mm),
resulting in a pooled SD of 27.1 mm.
A sample size of 110 evaluable patients per treatment
arm provides at least 95% power to detect a treatment
difference of 13.3 mm in change from baseline of VAS
pain score after 15 min with a pooled SD of 27.1 mm.
Approximately 220 patients will be randomised and
treated, and the drop-out rate is expected to be minimal.
This sample size will allow an overall power of the trial
to deliver statistically significant results for the complete
trial population.
The trial population will include a minimum of 88
children (40%) aged 6–8 years, 88 children (40%) aged
9–11 years and 44 adolescents (20%) aged 12–17 years.
An exploratory subgroup analysis per age range will be
conducted, but this is not expected to be sufficiently
powered to demonstrate statistical significance.
Statistical analysis plan
The primary analysis shall be an intention-to-treat (ITT)
analysis of the difference between methoxyflurane and
placebo on the VAS, to include all patients who are ran-
domised and receive trial treatment and undergo at least
one post-baseline efficacy assessment. A pragmatic con-
version of WBF-PRS scores to VAS scores (e.g. WBF-
PRS 2 = VAS 20mm, WBF-PRS 4 = VAS 40 mm, etc.)
will be completed. The primary model will be an analysis
of covariance (ANCOVA) of the VAS at 15 min following
the start of inhalation of trial treatment with baseline
pain as covariate, treatment and age group as fixed effect
and site as random effect using the ITT population. The
treatment effect shall be estimated as the average differ-
ence between the methoxyflurane-treated group and the
placebo group at 15 min. Pain scores taken after the ini-
tiation of a rescue medication will be included in the pri-
mary analysis. This approach is conservative for the
primary analysis and allows for patients with missing
data at any time point to be included in the analysis with
less bias than if patients are dropped from the analysis.
Sensitivity analysis of primary endpoint pain values shall
be performed using Worst Observation Carried Forward
(WOCF). To exclude the possibility that conversion of
any WBF-PRS scores (ordinal scale) into VAS scores
(continuous scale) significantly influences the outcome
of the trial, sensitivity analysis using a non-parametric
test (Wilcoxon rank-sum test) will be performed.
Various methods will be used for secondary endpoint
analyses. For treatment comparison of change from base-
line for continuous variables with more than one meas-
urement within a time period, repeated-measures analysis
employing restricted maximum likelihood (REML)-based
mixed-model repeated measures (MMRM) will be used.
For continuous variables with baseline value and one
post-baseline measurement, ANCOVA will be used, un-
less specified otherwise. Least square means (LSmeans),
SE, LSmeans difference, 95% confidence interval (CI) and
p-value will be presented. Logistic regression analyses ad-
justed for baseline will be performed for the binary vari-
ables, and the odds ratio and 95% CI for the odds ratio of
treatment group comparisons will be given.
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Analysis of safety will be for all randomised and
treated patients, and according to the treatment actually
received. Any protocol deviations will be defined and
classified as major (i.e. affecting the primary endpoint)
or minor before database lock and unblinding.
Demographic and baseline characteristics will be re-
corded prior to randomisation, and will be summarised
by treatment group for all patients who are randomised
and received trial treatment. Overall summaries will in-
clude descriptive statistics for continuous measures
(number of observations, mean, SD, median, minimum
and maximum) and for categorical measures (sample
size and frequency).
Interim analyses
A blinded interim analysis is planned to verify the sam-
ple size calculation and assumptions; if necessary, the
sample size will be modified. This analysis will be per-
formed as soon as the trial has been completed by at
least 30 patients in the age groups 6–8 years and 9–11
years and at least 15 adolescents. As this is a blinded in-
terim analysis, no adjustment of the significance level is
required.
Trial monitoring
The Sponsor has engaged the services of IQVIA™, the
Contract Research Organisation for the MAGPIE trial,
to perform all monitoring functions within the MAGPIE
trial. The monitors work in accordance with the stand-
ard operating procedures of IQVIA™, and have the same
rights and responsibilities as monitors from the Sponsor.
Monitoring visits are conducted according to all applic-
able regulatory requirements and standards. IQVIA™ is
responsible for coordinating investigator meetings, in-
vestigator teleconferences and for communicating im-
portant protocol modifications to sites, trial registries
and regulators.
Safety monitoring
An independent Data Safety Monitoring Board (DSMB)
is established for the trial. The DSMB is an independent
group of experts who will review ARs reported during
this trial. The DSMB comprises at least three members,
including at least one clinician and one statistician. This
board will meet at least once during the trial and add-
itionally in the event of a SAE where the event is associ-
ated with methoxyflurane administration.
Definitions for AE, AR, SAE and suspected unex-
pected serious adverse reactions (SUSAR) of the Clinical
Trials Regulation (EU No. 536/2014), based on the prin-
ciples of Good Clinical Practice, apply to the MAGPIE
trial. The AE reporting period begins from the point of
written consent until day 14 (with an allowed window
period of 2 days for the telephone follow-up call to be
performed). The Principal Investigator, or designee, re-
cords all directly observed AEs and all AEs reported by
the patient/parent during the follow-up telephone call.
The Principal Investigator, or designee, assesses all AEs
for seriousness, causality and severity and, if the AE is
related to the trial treatment, for expectedness. AEs are
assessed as unrelated, unlikely, possibly, probably or def-
initely related to the trial treatment, to the Penthrox® in-
haler device and to any trial procedure. All AEs will be
followed up to resolution, meaning that the patient has
returned to a baseline state of health or the Investigator
does not expect any further improvement or worsening
of the AE.
Any SAE is reported immediately (or no later than 24
h after site staff becoming aware of it), using the elec-
tronic SAE report form within the eCRF. This generates
an automatic email alert to the Sponsor’s pharmacovigi-
lance provider. As a backup, all SAEs should be reported
by fax/email to the Sponsor’s pharmacovigilance pro-
vider using the SAE paper report form, no later than 24
h after site staff becoming aware of it. The SAE report
will contain as much available information concerning
the SAE to enable the Sponsor (or an authorised repre-
sentative) to file a report, which satisfies regulatory
reporting requirements.
The Sponsor’s pharmacovigilance provider is respon-
sible for reporting all SUSARs and any other applicable
SAEs to regulatory authorities, ethics committees and
Investigators, in accordance with national regulations.
This will occur within 7 days for fatal and life-
threatening events and 15 days for other SUSARs, unless
otherwise required by national regulations. The Spon-
sor’s designee will also prepare an expedited report for
other safety issues where applicable.
Emergency unblinding
Blinded investigators are strongly discouraged from
requesting the blinding be broken for an individual pa-
tient, unless there is a patient safety issue that requires
unblinding and would change patient management. The
process for unblinding is handled through the IWRS
which is accessible at all times. The investigator should
inform the Sponsor or IQVIA™ prior to unblinding if
possible, or as soon as possible afterwards.
Confidentiality
The patient trial number is recorded on all documents
related to the trial. All personal information, including
patient name, is removed or rendered illegible from any
supportive documentation submitted with the eCRF,
such as laboratory or hospital records. Participant med-
ical information is confidential and disclosure to third
parties is prohibited.
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The Sponsor, or designee and auditor, may access pa-
tient records for the purpose of monitoring this trial,
auditing and managing progress details. Patient records
will only be accessed in secure facilities within the site in
order to check the information and verify the clinical trial
procedures, whilst maintaining patient confidentiality.
Dissemination
The results of the MAGPIE trial will be reported in a
clinical trial report, written in accordance with the Inter-
national Council for Harmonisation of Technical Re-
quirements for Pharmaceuticals for Human Use E3
guidelines, and will be submitted in accordance with
local regulations. Results will also be published in a
peer-reviewed journal or journals. Publications will be
distributed to participating centres, and throughout rele-
vant networks including PERUKI and other international
paediatric emergency medicine networks. Authorship
will be granted based on scientific input and recruitment
efforts and will be granted upon decision of a publica-
tion committee. This committee will include, among
others, the Chief Investigator and the Sponsor. Findings
will also be presented at relevant national and inter-
national scientific (e.g. emergency medicine, paediatric,
pain) conferences. Raw data will remain the intellectual
property of the Sponsor and are not currently planned
for release.
Discussion
The MAGPIE trial presents a number of challenges
which were carefully considered during the initial set-up
phase and at the initial and subsequent investigator
meetings.
Challenges and opportunities for paediatric emergency
research
Despite conducting a thorough and considered process
for the selection of sites, several elements of the MAG-
PIE trial are novel for many of the participating sites.
The trial demands efficient working in the early stages
of the patient journey, requiring quite complex organisa-
tional processes to be well thought out and constructed.
To date, successful recruitment has been achieved via
close communication between the participating sites,
IQVIA™ and the Sponsor, with leadership from PERUKI,
providing frequent opportunities to share best practice
in overcoming any obstacles to trial delivery. Specific ex-
amples include weekly recruitment emails, quarterly
newsletters, investigator teleconferences and face-to-face
investigator meetings. For many participating EDs, the
MAGPIE trial represents their first exposure to commer-
cial research, and is hence breaking new ground for the
PERUKI network.
Minimising delay to analgesia
The necessity of acquiring trial consent whilst simultan-
eously preventing or minimising any delay to analgesia
for patients who are in acute moderate to severe pain is
a considerable practical, administrative and ethical chal-
lenge. It is essential to ensure successful trial site en-
gagement by optimising the efficiency of trial activity,
particularly in the early screening and enrolment stages,
to prevent or minimise delays to appropriate analgesia
administration. Sites identify potential patients for
screening as soon as possible after ED arrival. Where
feasible, the preferred model is for dedicated research
nurses to identify patients immediately after registration
using the ED electronic patient management system,
and to assess them immediately, thus removing the ne-
cessity to wait in the standard queue for initial nurse as-
sessment/triage. For patients who meet the eligibility
criteria, the written information provided takes the form
of an initial brief summary sheet which contains all of
the essential trial information.
Placebo control in the context of moderate to severe pain
Half of the patients recruited to the MAGPIE trial will
receive trial treatment in the form of placebo. During
the consent process and during the trial training pro-
vided by the research nurse, it is emphasised that rescue
analgesia is available at any time on request. Further-
more, the treating blinded clinician is trained to assess
the patient at the 20-min time point and to consider the
need for rescue analgesia if the pain level has not de-
creased. The research nurse ensures that, before a pa-
tient is enrolled, there is a clinician who will be
immediately available to prescribe rescue analgesia or,
where possible, that the rescue analgesia is drawn up in
parallel with the study treatment.
Maintaining blinding
The time-critical subject of this trial and the properties
of methoxyflurane mean that the Penthrox® inhalers can-
not be loaded within a pharmacy clinical trials unit. For
this to occur within the ED, it is essential that several
members of the ED and research teams contribute to
the trial, working in pre-designated blinded and un-
blinded teams. Participating sites have each identified a
preparation area for the loading of the inhalers which is
separate from the standard clinical area. It is within this
preparation area that the unblinded investigators add the
drops of methoxyflurane onto the wristbands of the pla-
cebo inhalers, which provides the masking smell to pre-
vent the participants and blinded investigators from
distinguishing between active IMP and placebo. No
cross-over between blinded and unblinded teams is per-
mitted for the duration of the trial.
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Trial status
The concept and framework of the trial was originally
presented as a Paediatric Investigation Plan to the Paedi-
atric Committee (PDCO) of the European Medicine’s
Agency for review and approval, and this informed the
subsequent protocol design.
Recruitment started in July 2017 using a previous ver-
sion of the MEOF-002 protocol (version 3.0, 24 May
2017).
A substantial amendment (amendment number
“Protocol V4”) for the current protocol MEOF-002 ver-
sion 4.0 (22 June 2018) was reviewed and approved by
the following bodies:
 Research governance: Health Research Authority
(HRA) and Health and Care Research Wales
(HCRW) on 25 September 2018 (reference IRAS
220282) and Our Lady’s Children’s Hospital,
Crumlin, Ireland on 31 October 2018 (GEN/539/
17).
 Medicine regulators: Medicines & Healthcare
products Regulatory Agency (MHRA) on 21
September 2018 (reference 33,389/0002/001–0004)
and The Health Protection Regulatory Authority
(HPRA), Ireland on 28 September 2018 (reference
2,187,763).
The key changes within this amendment were as
follows:
 Addition of Entonox (50% nitrous oxide and 50%
oxygen mixture) to the list of permitted pre-hospital
analgesics, provided it was administered at least 30
min prior to ED arrival. This was in response to
feedback from sites, in order to reduce exclusion of
patients who were otherwise eligible for recruitment.
 Protocol V3.0 included two screening pain
assessments 5 min apart (measured using the VAS
or WBF-PRS), The first of these was replaced in
Protocol V4.0 with a “pre-screening” pain assess-
ment using whichever pain tool is standard practice
at each individual site. This removes the need for
three pain score assessments prior to randomisation
for those patients who follow the default triage
process within their ED.
 Clarification that, for patients requiring inpatient
admission, the time of such decision to admit
should be considered the discharge time in terms of
trial activity.
 Following feedback from sites on their standard of
care analgesic agents, the list of permitted rescue
medications was expanded to also include intranasal
ketamine and Entonox (50% nitrous oxide and 50%
oxygen mixture).
 Protocol V3.0 allowed for standard of care oral
analgesic medications (paracetamol and ibuprofen)
to be given only at the time of ED discharge. V4.0
also permits these medications:
 as concomitant medications alongside rescue
medication; and
 if there is a prolonged ED stay prior to discharge
or inpatient admission, provided administration
of trial treatment has ended.
All other changes were minor clarifications for any in-
consistencies between different sections of the protocol.
Recruitment adhering to protocol V4.0 is ongoing at the
time of manuscript submission.
At the start of February 2019, 117 patients have been
randomised to the trial, 96 of these have received trial
treatment and nine sites are currently open to recruit-
ment. Recruitment is scheduled to finish in July 2021.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOCX 60 kb)
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